1.	Phase I/II Study of Autologous Dendritic Cells Transduced With Adenoviruses Encoding the MART-1 and gp100 Melanoma Antigens Administered With or Without Interleukin-2 in Patients With Stage III or IV Melanoma (Summary Last Modified 07/2002) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GENZ-ML98-0501, DFCI-98258, NCT00004025
2.	Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed with MART-1 and gp100 Melanoma Antigens in Patients with High Risk Stage III or Completely Resected Metastatic Melanoma (Summary Last Modified 06/2002) Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-99-C-0132, NCT00019890
3.	Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100/MART Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: MCC-15383, 106566, NCI-P-8215, NCT01008527